Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions

Isabel Lam, Alain Ndayisaba, Amanda J. Lewis, YuHong Fu, Giselle T. Sagredo, Ludovica Zaccagnini, Jackson Sandoe, Ricardo L. Sanz, Aazam Vahdatshoar, Timothy D. Martin, Nader Morshed, Toru Ichihashi, Arati Tripathi, Nagendran Ramalingam, Charlotte Oettgen-Suazo, Theresa Bartels, Max Schäbinger, Erinc Hallacli, Xin Jiang, Amrita Verma, Challana Tea, Zichen Wang, Hiroyuki Hakozaki, Xiao Yu, Kelly Hyles, Chansaem Park, Thorold W. Theunissen, Haoyi Wang, Rudolf Jaenisch, Susan Lindquist, Beth Stevens, Nadia Stefanova, Gregor K. Wenning, Kelvin C. Luk, Rosario Sánchez‐Pernaute, Juan Carlos Gómez‐Esteban, Daniel Felsky, Yasujiro Kiyota, Nidhi Sahni, S. Stephen Yi, Chee-Yeun Chung, Henning Stahlberg, Isidró Ferrer, Johannes Schöneberg, Stephen J. Elledge, Ulf Dettmer, Glenda M. Halliday, Tim Bartels, Vikram KhuranabioRxiv 2022 · DOI

TL;DR

This paper introduces a novel, rapid, and versatile iPSC-based system for modeling protein aggregation diseases like Parkinson's. By overcoming limitations of existing models, it allows for detailed study of inclusion formation, subtype diversity, and their toxic consequences, paving the way for better understanding and therapeutic development.

What Problem Does This Paper Address?

Neurodegenerative diseases like Parkinson's are characterized by the accumulation of abnormal protein aggregates, known as inclusions, within brain cells. These inclusions are surprisingly diverse, varying in their composition and structure, yet the significance of this heterogeneity is poorly understood. Current induced pluripotent stem cell (iPSC) models, while promising for disease modeling, are often slow to develop these inclusions and can be difficult to manipulate for large-scale studies. This lack of tractable, rapid models that capture the complexity of inclusion subtypes hinders our ability to understand how these different inclusions form, interact, and ultimately contribute to neuronal death, and to develop effective treatments.

Methods

The researchers developed a powerful iPSC-based platform using the piggyBac (pB) transposon system. This system allows for rapid, virus-free, and scalable genetic modification of iPSCs. Key methodological innovations include:

  • One-step transdifferentiation: iPSCs are quickly converted into specific CNS cell types (neurons and astrocytes) by overexpressing lineage-specific transcription factors.
  • Rapid inclusion formation: This is achieved through various methods, including:
  • Targeted transgene integration: Using safe harbor loci like AAVS1 or lineage-specific loci like STMN2 for controlled expression of aggregation-prone proteins.
  • All-in-one pB plasmids: Combining the transdifferentiation factors and the aggregation-prone protein in a single construct for simultaneous induction.
  • Exogenous seeding: Using pre-formed protein fibrils (PFFs) to trigger inclusion formation.
  • Spontaneous aggregation: Utilizing specific protein mutations (e.g., SNCA-3K) that promote aggregation without external seeding.
  • Longitudinal single-cell tracking: A custom algorithm was developed to monitor individual neurons and their inclusions over time, assessing cell survival and the dynamics of inclusion formation.
  • Advanced imaging techniques: Including lattice light-sheet microscopy for 3D visualization of inclusion dynamics.
  • Protein-protein interaction mapping: Employing membrane yeast two-hybrid (MYTH) and proximity ligation assay (PLA) to identify proteins interacting with or sequestered within inclusions.
  • Genome-wide CRISPR screens: Used in cell lines to identify genes whose depletion exacerbates toxicity in the presence of specific inclusion subtypes.

Datasets

The study utilized:

  • Human iPSC lines: Derived from patients with synucleinopathies (e.g., Parkinson's disease, Multiple System Atrophy) and healthy controls.
  • Postmortem human brain tissue: From individuals with sporadic Parkinson's disease, A53T mutation carriers, and controls, used for validation and comparison.
  • ROS/MAP dataset: A population-based study dataset used for analyzing differential gene expression in relation to Lewy body pathology.

No new benchmarks were introduced, but the study aimed to create models that more accurately recapitulate the complexity of human brain pathology.

Key Insights and Ideas

  • Inclusion heterogeneity is functionally significant: The study strongly suggests that different subtypes of alpha-synuclein inclusions have distinct biophysical properties and toxic effects, rather than being simple variations on a theme.
  • Lipid-rich inclusions are a distinct and toxic subtype: These inclusions form spontaneously, are sensitive to specific drug treatments, and appear to interact with fibril-rich inclusions.
  • Fusion events between inclusion subtypes may occur and impact survival: The observation of neuritic lipid-rich inclusions merging with somatic lipid-rich inclusions, and the subsequent improved survival in "converter" cells, suggests a dynamic interplay.
  • Novel markers for inclusion subtypes can be identified: Techniques like proximity ligation assay and co-localization studies revealed Rab proteins (especially Rab8) as potential markers for lipid-rich inclusions, offering more granular classification than pS129 alone.
  • RhoA is a key player in toxic inclusion formation: Genetic screens and protein interaction studies highlighted RhoA as a protein whose sequestration into inclusions is likely to be particularly toxic, and it serves as a marker for these toxic subtypes.

Key Results

  • The developed iPSC platform allows for rapid induction of CNS cells and protein aggregation within weeks, overcoming a major limitation of previous models.
  • The models successfully recapitulated known fibril- and lipid-rich inclusion subtypes observed in postmortem brain.
  • Single-cell tracking revealed that somatic inclusions, rather than neuritic ones, are particularly toxic to neurons.
  • Lipid-rich inclusions were found to form spontaneously in specific models and were distinct from fibril-rich inclusions.
  • Fusion events between lipid-rich and fibril-rich inclusions were observed, and surprisingly, "converter" cells (where lipid-rich inclusions transitioned to a different state) showed improved survival.
  • RhoA was identified as a novel marker for toxic, lipid-rich inclusions and its sequestration was linked to increased toxicity.
  • The platform enabled the identification of potential therapeutic targets by pinpointing proteins whose depletion exacerbated inclusion-induced toxicity.

Limitations and Future Work

The authors acknowledge several limitations:

  • Doxycycline dependence: Some models rely on doxycycline for transgene induction, which is known to have biological activity and could confound results, particularly in studies of mitochondrial function. The team is developing doxycycline-independent alternatives.
  • Random integration of piggyBac: While polyclonal lines are used to mitigate this, random integration can lead to unpredictable genetic effects and genome instability. They are also exploring single-site integration methods.
  • Overexpression artifacts: While the models recapitulate many aspects of disease pathology, the use of transgenic overexpression might lead to non-physiologic accumulation of proteins.
  • Limited maturation and aging: The current models may not fully capture the long-term, age-related changes seen in postmortem brains. Future work could focus on accelerating maturation and aging in these models.
  • Absence of glia and neuroinflammation: The current models primarily focus on neurons. Future studies should incorporate glia and investigate neuroinflammatory responses, which are crucial in disease pathogenesis.
  • 2D culture limitations: Non-cell-autonomous effects and complex interactions might be better recapitulated in 3D sphere and organoid systems.

Future directions include:

  • Expanding the platform to study other proteinopathies beyond synucleinopathies.
  • Developing more reproducible 3D co-culture systems.
  • Utilizing engraftment of iPSC-derived models into animal systems for more disease-relevant timescales.
  • Applying the platform for patient-specific diagnostics (e.g., radiotracers) and therapeutic testing (e.g., antibodies).

Summary updated

Abstract

ABSTRACT Intracellular inclusions accompanying neurodegeneration are histopathologically and ultrastructurally heterogeneous but the significance of this heterogeneity is unclear. iPSC models, while promising for disease modeling, do not form inclusions in a reasonable timeframe and suffer from limited tractability. Here, we developed an iPSC toolbox utilizing piggyBac-based or targeted transgenes to rapidly induce CNS cells with concomitant expression of aggregation-prone proteins. This system is amenable to screening and longitudinal tracking at single-cell and single-inclusion resolution. For proof-of-principle, cortical neuron α-synuclein “inclusionopathy” models were engineered to form inclusions through exogenous seeding or α-synuclein mutation. These models recapitulated known fibril- and lipid-rich inclusion subtypes, uncovering dynamic interactions between them, and refined the classification of inclusions in postmortem brain. Genetic-modifier and protein-interaction screens pinpointed proteins like RhoA whose sequestration into specific inclusion subtypes is likely to be toxic. This iPSC platform should enhance our understanding of proteinaceous pathologies in neurodegeneration and facilitate therapeutics development.
BibTeX
@misc{lam2022rapid,
  author = {Isabel Lam and Alain Ndayisaba and Amanda J. Lewis and YuHong Fu and Giselle T. Sagredo and Ludovica Zaccagnini and Jackson Sandoe and Ricardo L. Sanz and Aazam Vahdatshoar and Timothy D. Martin and Nader Morshed and Toru Ichihashi and Arati Tripathi and Nagendran Ramalingam and Charlotte Oettgen-Suazo and Theresa Bartels and Max Schäbinger and Erinc Hallacli and Xin Jiang and Amrita Verma and Challana Tea and Zichen Wang and Hiroyuki Hakozaki and Xiao Yu and Kelly Hyles and Chansaem Park and Thorold W. Theunissen and Haoyi Wang and Rudolf Jaenisch and Susan Lindquist and Beth Stevens and Nadia Stefanova and Gregor K. Wenning and Kelvin C. Luk and Rosario Sánchez‐Pernaute and Juan Carlos Gómez‐Esteban and Daniel Felsky and Yasujiro Kiyota and Nidhi Sahni and S. Stephen Yi and Chee-Yeun Chung and Henning Stahlberg and Isidró Ferrer and Johannes Schöneberg and Stephen J. Elledge and Ulf Dettmer and Glenda M. Halliday and Tim Bartels and Vikram Khurana},
  title = {{Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions}},
  year = {2022},
  doi = {10.1101/2022.11.08.515615},
  howpublished = {bioRxiv},
}

Loading related content...

Figure